Daisy Pharma, Inc.

Daisy Pharma is an accelerated drug development company that takes existing Food and Drug Administration (FDA) approved drugs and combines them into new drug formulations known as Fixed Dose Combinations (FDC's). In developing our FDC's, we select only those drug combinations whose synergistic benefits have been adequately demonstrated by pre-clinical research in animal models and clinical research in humans. Our drugs qualify for an expedited route to approval because most of data that is required by the FDA to prove drug safety and efficacy already exists.

Our Team includes a diverse group of FDA regulatory, drug development, and intellectual property experts that develop Investigational New Drugs (IND) through the FDA's abbreviated 505(b)(2) approval pathway. We secure all of the necessary intellectual property protections for our drugs, including patent rights in both the US and international markets.